Medical Retina Fellowship

医学视网膜奖学金

基本信息

批准号：
10706221
负责人：
Catherine Cukras
金额：
$ 99.77万
依托单位：
NATIONAL EYE INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10706221
关键词：
Age related macular degeneration Blood Clinical Clinical Research Collaborations Collection DNA Dark Adaptation Diabetic Retinopathy Epidemiology Eye diseases Faculty Fellowship Genotype HIV Hydroxychloroquine Individual Inherited Intervention Studies Medical National Cancer Institute National Eye Institute National Human Genome Research Institute National Institute of Neurological Disorders and Stroke Natural History Nerve Degeneration Nursing Faculty Participant Patient Care Patients Phase Phenotype Protocols documentation Resources Retina Retinal Diseases Retinal Vein Occlusion Serous Telangiectasis Testing Toxic effect Training Translational Research Von Hippel-Lindau Syndrome X-Linked Retinoschisis age related biobank clinical application clinical care clinical trial participant epidemiology study experience follow-up gene therapy geographic atrophy high standard inhibitor macula novel recruit screening

项目摘要

A number of medical retinal protocols have been conducted at the National Eye Institute under the Division of Epidemiology and Clinical Applications. This includes both interventional studies (phase I and/or or II) and natural history studies for multiple common and rare retinal diseases. These include age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, macular telangiectasia, hydroxychloroquine retinal toxicity, central serous chorioretinopathy, inherited retinal diseases, and Von Hippel Lindau (VHL) disease. In addition, a screening study provides participants for potential recruitment to these trials and natural history studies. The interventional studies include those related to treatment with a microglial inhibitor for geographic atrophy in AMD; novel treatments for retinal disease in VHL (in collaboration with the National Cancer Institute); a gene therapy approach for X-linked retinoschisis; and a neuroprotective treatment for macular telangiectasia type 2. The natural history studies include multiple related to AMD (follow up of Age-Related Eye Disease Study (AREDS) and AREDS2; studies of dark adaptation in patients with AMD; the AMD Ryan Initiative Study; the geographic atrophy natural history study), as well as those related to hydroxychloroquine retinal toxicity and macular telangiectasia. The Biobank protocol includes collection of blood (DNA) for multiple retinal diseases. Other collaborative studies underway include retinal findings in individuals with HIV-related neurodegeneration (with NINDS), and genotype-phenotype studies of AMD (with NHGRI).

在流行病学和临床应用程序的情况下，国家眼科研究所已经进行了许多医疗视网膜方案。这包括介入研究（I期和/或II期）以及多种常见和罕见视网膜疾病的自然史研究。其中包括与年龄相关的黄斑变性（AMD），糖尿病性视网膜病变，视网膜静脉阻塞，黄斑毛细血管扩张，羟基氯喹毒性视网膜毒性，中央浆液性脉络膜性肾上腺病，视网膜疾病，遗传性视网膜疾病和Von Hippel Lindau（Von Hippel Lindau（VHL））。此外，筛查研究为参与者提供了潜在的这些试验和自然历史研究的招募。介入研究包括与用小胶质细胞抑制剂治疗AMD中的地理萎缩有关的研究。 VHL视网膜疾病的新型治疗方法（与国家癌症研究所合作）； X连锁视网膜的基因治疗方法；以及针对2型黄斑毛细血管扩张的神经保护治疗。自然史研究包括与AMD相关的多种（随访与年龄相关的眼病研究（AREDS）和AREDS2； AMD患者的黑暗适应性研究； AMD Ryan Initiative研究； AMD Ryan Initiative研究；《自然历史研究》，以及与羟基氯喹氯甲氯性视网膜毒性和黄斑型teplangiectia有关的研究。生物库方案包括用于多种视网膜疾病的血液（DNA）。正在进行的其他协作研究包括与HIV相关神经变性（Ninds）和AMD基因型 - 表型研究（与NHGRI）的个体中的视网膜发现。